Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression

Journal of Psychiatric Research

Volumn 78, Issue , 2016, Pages 1-10

  Russo, Emilio ^a   Leo, Antonio ^a   Crupi, Rosalia ^b   Aiello, Rossana ^a   Lippiello, Pellegrino ^c   Spiga, Rosangela ^a   Chimirri, Serafina ^a   Citraro, Rita ^a   Cuzzocrea, Salvatore ^b   Constanti, Andrew ^d   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anxiety; Cognitive function; Depression; Mice; MTOR; Neurogenesis

Indexed keywords

BETAMETHASONE SODIUM PHOSPHATE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; ELEVATED PLUS MAZE TEST; FORCED SWIM TEST; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LEARNING; MALE; MEMORY; MORRIS WATER MAZE TEST; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SYNAPTOGENESIS; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANXIETY; CHEMICALLY INDUCED; COGNITIVE DYSFUNCTION; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; HIPPOCAMPUS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZATION; SYNAPSE;

ADMINISTRATION, ORAL; ANIMALS; ANXIETY; COGNITIVE DYSFUNCTION; DEPRESSION; DISEASE MODELS, ANIMAL; EVEROLIMUS; HIPPOCAMPUS; LEARNING; MALE; MEMORY; MICE, INBRED DBA; NEUROGENESIS; RANDOM ALLOCATION; SYNAPSES; TOR SERINE-THREONINE KINASES;

EID: 84961821201     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2016.03.008     Document Type: Article

References (61)

1. Abelaira H.M., Reus G.Z., Neotti M.V., Quevedo J. The role of mTOR in depression and antidepressant responses. Life Sci. 2014, 101:10-14.
2. Aiello R., Crupi R., Leo A., Chimirri S., Rispoli V., Marra R., et al. Long-term betamethasone 21-phosphate disodium treatment has distinct effects in CD1 and DBA/2 mice on animal behavior accompanied by opposite effects on neurogenesis. Behav. Brain Res. 2015, 278:155-166.
3. Brewster A.L., Lugo J.N., Patil V.V., Lee W.L., Qian Y., Vanegas F., et al. Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage. PLoS One 2013, 8:e57808.
4. Cambiaghi M., Cursi M., Magri L., Castoldi V., Comi G., Minicucci F., et al. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. Neuropharmacology 2013, 67:1-7.
5. Campbell S., Marriott M., Nahmias C., MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am. J. Psychiatry 2004, 161:598-607.
6. Citraro R., Chimirri S., Aiello R., Gallelli L., Trimboli F., Britti D., et al. Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia 2014, 55:1284-1291.
7. Citraro R., Leo A., De Fazio P., De Sarro G., Russo E. Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy. Br. J. Pharmacol. 2015, 172:3177-3188.
8. Cleary C., Linde J.A., Hiscock K.M., Hadas I., Belmaker R.H., Agam G., et al. Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res. Bull. 2008, 76:469-473.
9. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Tomkins D.M. Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol. Biochem. Behav. 1989, 32:777-785.
10. Crupi R., Mazzon E., Marino A., La Spada G., Bramanti P., Battaglia F., et al. Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. BMC Complement. Altern. Med. 2011, 11:7.
11. Crupi R., Mazzon E., Marino A., La Spada G., Bramanti P., Cuzzocrea S., et al. Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. J. Pineal Res. 2010, 49:123-129.
12. Curatolo P., Moavero R. mTOR inhibitors in tuberous sclerosis complex. Curr. Neuropharmacol. 2012, 10:404-415.
13. Dubois M., Le Joncour V., Tonon M.C., Anouar Y., Proust F., Morin F., et al. Evaluation of the impact of the cancer therapy everolimus on the central nervous system in mice. PLoS One 2014, 9:e113533.
14. Duman R.S., Li N., Liu R.J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62:35-41.
15. Egan D., Kim J., Shaw R.J., Guan K.L. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy 2011, 7:643-644.
16. Eisch A.J., Petrik D. Depression and hippocampal neurogenesis: a road to remission?. Science 2012, 338:72-75.
17. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:70-75.
18. Fish E.W., Riday T.T., McGuigan M.M., Faccidomo S., Hodge C.W., Malanga C.J. Alcohol, cocaine, and brain stimulation-reward in C57Bl6/J and DBA2/J mice. Alcohol Clin. Exp. Res. 2010, 34:81-89.
19. Gassen N.C., Hartmann J., Zschocke J., Stepan J., Hafner K., Zellner A., et al. Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans. PLoS Med. 2014, 11:e1001755.
20. Gourley S.L., Swanson A.M., Koleske A.J. Corticosteroid-induced neural remodeling predicts behavioral vulnerability and resilience. J. Neurosci. 2013, 33:3107-3112.
21. Hadamitzky M., Herring A., Keyvani K., Doenlen R., Krugel U., Bosche K., et al. Acute systemic rapamycin induces neurobehavioral alterations in rats. Behav. Brain Res. 2014, 273:16-22.
22. Halloran J., Hussong S.A., Burbank R., Podlutskaya N., Fischer K.E., Sloane L.B., et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 2012, 223:102-113.
23. Hanson N.D., Owens M.J., Nemeroff C.B. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 2011, 36:2589-2602.
24. Hasskarl J. Everolimus. Recent Results Cancer Res. 2014, 201:373-392.
25. Hodes G.E., Brookshire B.R., Hill-Smith T.E., Teegarden S.L., Berton O., Lucki I. Strain differences in the effects of chronic corticosterone exposure in the hippocampus. Neuroscience 2012, 222:269-280.
26. Howell K.R., Kutiyanawalla A., Pillai A. Long-term continuous corticosterone treatment decreases VEGF receptor-2 expression in frontal cortex. PLoS One 2011, 6:e20198.
27. Jernigan C.S., Goswami D.B., Austin M.C., Iyo A.H., Chandran A., Stockmeier C.A., et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1774-1779.
28. Jia J., Le W. Molecular network of neuronal autophagy in the pathophysiology and treatment of depression. Neurosci. Bull. 2015, 31:427-434.
29. Kendler K.S., Karkowski L.M., Prescott C.A. Causal relationship between stressful life events and the onset of major depression. Am. J. Psychiatry 1999, 156:837-841.
30. Kotulska K., Chmielewski D., Borkowska J., Jurkiewicz E., Kuczynski D., Kmiec T., et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur. J. Paediatr. Neurol. 2013, 17:479-485.
31. Lang U.E., Heger J., Willbring M., Domula M., Matschke K., Tugtekin S.M. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement. Transpl. Proc. 2009, 41:4285-4288.
32. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
33. Majumder S., Caccamo A., Medina D.X., Benavides A.D., Javors M.A., Kraig E., et al. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 2012, 11:326-335.
34. Martinez-Sanchis S., Bernal M.C., Montagud J.V., Candela G., Crespo J., Sancho A., et al. Effects of immunosuppressive drugs on the cognitive functioning of renal transplant recipients: a pilot study. J. Clin. Exp. Neuropsychol. 2011, 33:1016-1024.
35. Mitchell P.B., Parker G.B., Gladstone G.L., Wilhelm K., Austin M.P. Severity of stressful life events in first and subsequent episodes of depression: the relevance of depressive subtype. J. Affect Disord. 2003, 73:245-252.
36. Murray F., Smith D.W., Hutson P.H. Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. Eur. J. Pharmacol. 2008, 583:115-127.
37. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13:1161-1169.
38. O'Reilly T., McSheehy P.M., Kawai R., Kretz O., McMahon L., Brueggen J., et al. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother. Pharmacol. 2010, 65:625-639.
39. Paliouras G.N., Hamilton L.K., Aumont A., Joppe S.E., Barnabe-Heider F., Fernandes K.J. Mammalian target of rapamycin signaling is a key regulator of the transit-amplifying progenitor pool in the adult and aging forebrain. J. Neurosci. 2012, 32:15012-15026.
40. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31:464-468.
41. Park S.W., Lee J.G., Seo M.K., Lee C.H., Cho H.Y., Lee B.J., et al. Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons. Int. J. Neuropsychopharmacol. 2014, 17:1831-1846.
42. Petrik D., Lagace D.C., Eisch A.J. The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building?. Neuropharmacology 2012, 62:21-34.
43. Raman L., Kong X., Gilley J.A., Kernie S.G. Chronic hypoxia impairs murine hippocampal development and depletes the postnatal progenitor pool by attenuating mammalian target of rapamycin signaling. Pediatr. Res. 2011, 70:159-165.
44. Raman L., Kong X., Kernie S.G. Pharmacological inhibition of the mTOR pathway impairs hippocampal development in mice. Neurosci. Lett. 2013, 541:9-14.
45. Russo E., Andreozzi F., Iuliano R., Dattilo V., Procopio T., Fiume G., et al. Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release. Brain Behav. Immun. 2014, 42:157-168.
46. Russo E., Chimirri S., Aiello R., De Fazio S., Leo A., Rispoli V., et al. Lamotrigine positively affects the development of psychiatric comorbidity in epileptic animals, while psychiatric comorbidity aggravates seizures. Epilepsy Behav. 2013, 28:232-240.
47. Russo E., Citraro R., Constanti A., De Sarro G. The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis. Mol. Neurobiol. 2012, 46:662-681.
48. Russo E., Citraro R., Davoli A., Gallelli L., Di Paola E.D., De Sarro G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013, 64:371-379.
49. Russo E., Citraro R., Donato G., Camastra C., Iuliano R., Cuzzocrea S., et al. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 2013, 69:25-36.
50. Russo E., Citraro R., Scicchitano F., De Fazio S., Perrotta I., Di Paola E.D., et al. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 2011, 52:1341-1350.
51. Russo E., Citraro R., Scicchitano F., Urzino A., Marra R., Rispoli V., et al. Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. Behav. Brain Res. 2011, 225:373-376.
52. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
53. Scheuing L., Chiu C.T., Liao H.M., Chuang D.M. Antidepressant mechanism of ketamine: perspective from preclinical studies. Front. Neurosci. 2015, 9:249.
54. Sousa N., Lukoyanov N.V., Madeira M.D., Almeida O.F., Paula-Barbosa M.M. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. Neuroscience 2000, 97:253-266.
55. Spilman P., Podlutskaya N., Hart M.J., Debnath J., Gorostiza O., Bredesen D., et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010, 5:e9979.
56. Starkman M.N. Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol. Metab. Clin. North Am. 2013, 42:477-488.
57. Sterner E.Y., Kalynchuk L.E. Behavioral and neurobiological consequences of prolonged glucocorticoid exposure in rats: relevance to depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:777-790.
58. Tang S.W., Helmeste D., Leonard B. Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review. World J. Biol. Psychiatry 2012, 13:402-412.
59. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1:848-858.
60. Wong M. Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed. J. 2013, 36:40-50.
61. Zschocke J., Zimmermann N., Berning B., Ganal V., Holsboer F., Rein T. Antidepressant drugs diversely affect autophagy pathways in astrocytes and neurons-dissociation from cholesterol homeostasis. Neuropsychopharmacology 2011, 36:1754-1768.